Boehringer Ingelheim


Metro Drug
Concise Prescribing Info
As monotherapy or in combination w/ other glucose-lowering drugs including insulin in the treatment of type 2 DM when diet & exercise alone do not provide adequate glycemic control. Patients w/ type 2 DM & established CV disease to reduce the risk of CV death; should be used in conjunction w/ other measures to reduce CV risk in line w/ the current standard of care.
Dosage/Direction for Use
Initially 10 mg once daily, may be increased to 25 mg once daily in patients requiring additional glycemic control. Lower dose when combined w/ sulphonylurea or insulin may be considered to reduce risk of hypoglycemia.
May be taken with or without food: Swallow whole w/ water.
Special Precautions
Not for use in patients w/ type 1 diabetes. Patients at risk of ketoacidosis while on treatment include patients on a very low carbohydrate diet, w/ an acute illness, pancreatic disorders suggesting insulin deficiency (eg, type 1 diabetes, history of pancreatitis or pancreatic surgery), insulin dose reduction (including insulin pump failure), alcohol abuse, severe dehydration, w/ history of ketoacidosis. Discontinue if ketoacidosis is suspected. Discontinue & institute prompt treatment in case of necrotizing fasciitis of the perineum (Fournier's gangrene). Patients for whom an empagliflozin-induced drop in BP could pose a risk eg, w/ known CV disease & on antihypertensive therapy w/ history of hypotension or patients ≥75 yr. Monitor vol status & electrolytes in case of conditions that may lead to fluid loss (eg, GI illness). Interrupt treatment temporarily in patients w/ complicated UTI. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.Not recommended for patients w/ renal impairment (eGFR <30 mL/min/1.73 m2). Pregnancy & lactation. Childn <18 yr. Elderly ≥85 yr.
Adverse Reactions
Hypoglycaemia. Vag moniliasis, vulvovaginitis, balanitis & other genital infections, UTI (including pyelonephritis & urosepsis), necrotizing fasciitis of the perineum (Fournier's gangrene); ketoacidosis; pruritus, allergic skin reactions (eg, rash, urticaria), angioedema; vol depletion; increased urination, dysuria; thirst; decreased GFR; increased blood creatinine, hematocrit & serum lipids.
Drug Interactions
May add to the diuretic effect of thiazide & loop diuretics & may increase risk of dehydration & hypotension. May increase risk of hypoglycemia w/ insulin & insulin secretagogues eg, sulphonylureas. May interfere w/ 1, 5-anhydroglucitol (1,5-AG) assay.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BK03 - empagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
Jardiance FC tab 10 mg
30's (P1,448.4/box)
Jardiance FC tab 25 mg
30's (P1,500/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in